Business Wire

J-Pop Stars Pump up the World’s Largest Projection Mapping Show at the Tokyo Metropolitan Government Building

14.8.2024 07:44:00 EEST | Business Wire | Press release

Share

A meteoric J-pop duo with a huge global following has pitched in to boost the world’s largest projection mapping show and help illuminate midsummer nights in Tokyo.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240808176674/en/

YOASOBI / Butai ni Tatte (Standing on the Stage) (Photo: Business Wire)

An artwork, combining YOASOBI’s up-tempo vocal and instrumental music with a riot of images and colors, made its debut on the TOKYO Night & Light program on July 26. The nightly show uses the exterior of the 243-meter-tall Tokyo Metropolitan Government (TMG) No. 1 Building as its screen. Three other projections created by internationally acclaimed artists also joined the menu over the same weekend.

YOASOBI – female vocalist Ikura, 23, and male singer-songwriter Ayase, 30 - has contributed the newly composed “Butai ni Tatte (Standing on the Stage),” which echoes the emotions of athletes ready for competition. The song has been adopted by Japan’s public broadcasting corporation NHK as a theme song for its sports programs, and its first Night & Light presentation was timed to coincide with the Paris Olympics opening ceremony.

For the first screening, a horde of people gathered at the Citizens’ Plaza at the foot of the 48-story building, a landmark in the business and entertainment hub of Shinjuku. They watched animated silhouette images of runners and other athletes romp around on the wall.

The Night & Light project has lived up to the TMG’s goal of creating a “new tourism resource to color Tokyo’s nightlife,” attracting 280,000 visitors in five months since its launch on February 25. Projected onto an area, 127 meters by 110 meters, the show has been certified by Guinness World Records™ as the “largest architectural projection-mapped display (permanent).”

Screened every half an hour between 7:30 p.m. and 9:30 p.m. at present, the program strings together a few projections for 15 minutes. On weekends and holidays, the series feature crowd pullers such as the world-famous Japanese movie monster Godzilla and a work inspired by traditional Japanese Ukiyo-e paintings. “Standing on the Stage,” 3.5 minutes long, is to be screened every night for the time being.

Meaning a “night out,” YOASOBI is a global household name five years after its debut. Its hit “Idol,” the theme tune for the TV animation “Oshi no Ko,” became the first Japanese song to top Billboard’s Global (excluding U.S.) chart in June last year. It was also acknowledged as Japan’s best popular song in terms of royalties in the year to March 2024.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240808176674/en/

Contacts

TOKYO Night & Light PR Office
press@tokyonightandlight.jp

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Bregal Milestone Backs Nethive With Majority Growth Investment and JoyComm Acquisition22.10.2026 11:00:00 EEST | Press release

Bregal Milestone, a leading European software growth private equity firm, today announced a majority growth investment in Nethive S.p.A. (“Nethive” or the “Company”), a leading Italian cybersecurity services and software provider. Alongside its investment in Nethive, Bregal Milestone has also backed Nethive’s acquisition of IT security specialist Joy Comm S.r.l. (“JoyComm”). Founded in 2014 by Alessandro Bellato and Diego Rocco, Nethive has become a trusted cybersecurity partner to blue-chip enterprises, SMEs, and public-sector organizations across Italy. Its platform spans managed security services, professional services and technology resale, helping organizations protect critical infrastructure and networks, strengthen cyber resilience and reduce operational complexity. Nethive combines deep technical expertise with 24/7 monitoring, threat detection and response, risk and vulnerability management, infrastructure protection and specialist consultancy. The Company serves more than 250

EOS and VOP CZ Sign Memorandum of Understanding to Explore Cooperation on Czech Programmes22.10.2026 10:00:00 EEST | Press release

EOS Defence Systems (EOS) and VOP CZ have signed a Memorandum of Understanding (MoU) at Future Forces Forum in Prague to explore cooperation on wheeled armoured vehicle programmes for the Czech Army and other future defence projects in the Czech Republic and Europe where VOP CZ is involved. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261021408045/en/ EOS and VOP CZ sign a Memorandum of Understanding at Future Forces Forum in Prague. Left to right: Martin van de Voorde, Sales Director Europe, EOS; Vlastimil Navrátil, Managing Director, VOP CZ; Pavla Ungrová, Sales Director, VOP CZ; Rear Admiral Richard Caton, Australia’s Military Representative to NATO and the EU; Group Captain Michael Schleeman, Australia’s Defence Attaché; and Matej Pupák, Program Lead, VOP CZ. The agreement brings together EOS' expertise in advanced remote weapon systems (RWS) with VOP CZ's established capabilities in military vehicle integration, produ

Ferrer and Prilenia Announce Authorization for EU Initiation of Confirmatory PRECISE-HD Study of Pridopidine in Huntington's Disease22.10.2026 10:00:00 EEST | Press release

Ferreri and Prilenia Therapeutics B.V.today announced that the confirmatory Phase 3 PRECISE-HD study of investigational pridopidine in Huntington's disease (HD) has received authorization to begin in participating EU Member States (EU CT number: 2026-526093-16-00, NCT07609108). Recruitment in the EU is expected to commence this month, joining currently recruiting sites in the US and UK, with Canada to follow. Designed to evaluate the efficacy and safety of pridopidine (administered as an oral capsule twice a day), and to generate data for regulatory evaluation, the global, approximately 400-participant, randomized, double-blind, placebo-controlled PRECISE-HD study will assess the clinical effect of the investigational treatment on disease progression, functional capacity, motor function, cognition, speech and quality of life. “The initiation of PRECISE-HD in Europe marks a milestone for the Huntington’s disease research community. This confirmatory Phase 3 study has been designed to bu

IQM Quantum Computers Announces Conference Call to Report Third Quarter 2026 Financial Results on November 5, 202622.10.2026 09:00:00 EEST | Press release

As published previously, IQM Quantum Computers Plc (Nasdaq: IQMX) ("IQM" or the "Company"), a global leader in superconducting quantum computers, will report financial results for the third quarter 2026 on Thursday, November 5, 2026. CEO Dr. Jan Goetz and CFO Jan Kuerschner will host a conference call at 3:00 PM EET / 2:00 PM CET / 8:00 AM EST on the same day followed by a Q&A session with analysts. Conference Call and Webcast A live audio webcast of the conference call will be available to the public through the link below and can be accessed in the News & Events section of IQM's Investor Relations website at https://investors.iqm.tech/. A replay of the call will be available at the same location for one year following the call. Participation in the Q&A during the conference call will require registration using the link below. Date: Thursday, November 5, 2026 Time: 3:00 PM EET / 2:00 PM CET / 8:00 AM EST Webcast Link: https://edge.media-server.com/mmc/p/syqjnhp6To ask questions on the

Galderma Delivers Net Sales of 4.765 B USD in the First Nine Months, Up 25.1% at Constant Currency Year-on-Year, and Raises Full-Year Net Sales Guidance22.10.2026 08:00:00 EEST | Press release

Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its sales performance for the first nine months of 2026. Record net sales of 4.765 billion USD for thefirst nine months of 2026, representing 25.1% year-on-year growth at constant currency1, predominantly driven by volume and complemented by favorable mix. Broad-based double-digit growth across geographies and product categories, reflecting strong execution of Galderma’s proven integrated dermatology strategy, with stand-out performance in Therapeutic Dermatology, across both Nemluvio and the mature portfolio, as well as in Dermatological Skincare and Neuromodulators. Continued market outperformance across all three product categories, with net sales growth year-on-year at constant currency of 13.2% in Injectable Aesthetics, 16.2% in Dermatological Skincare, and 64.4% in Therapeutic Dermatology (with Nemluvio net sales of 735 million USD). Strengthening Galderma’s dermatology platform, with the pre

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye